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A b s t r A c t
bAckground: Sodium nitroprusside has successfully been an excellent choice when 
considering a decrease in systemic vascular resistance in the critical care setting. How-
ever, reflex tachycardia and ventilation-perfusion mismatch are possible side effects of 
this agent. To maintain cardiac output, cerebral perfusion pressure, and concurrently 
drop systemic vascular resistance (SVR), low-dose epinephrine or dopamine are vi-
able options. The aim of this paper is to conduct dose-response simulations to identify 
the equivalent dopamine, epinephrine, and nitroprusside infusion doses to decrease 
the systemic vascular resistance by 20% and by 40% from baseline resting values.
Methods: Three studies were identified in the literature which reported epineph-
rine, dopamine, and sodium nitroprusside infusion doses with corresponding SVR 
responses. Infusion doses were normalized to mcg/kg/min and SVR values were nor-
malized and scaled to the percent decrease (%SVR) in SVR from baseline resting 
values. The original published studies were mathematically modeled and the Hill 
equation parameters used for further dose-response simulations of a virtual popula-
tion. One-hundred patients were simulated various doses resulting in corresponding 
%SVR responses for each of the three drugs.
results: Equivalent infusion doses achieving an approximate 20-25% decrease in 
SVR from baseline, were identified for epinephrine, dopamine, and sodium nitro-
prusside. Moreover, equivalent infusion doses were identified for epinephrine and 
nitroprusside to decrease the SVR by 40% from baseline.
conclusion: Even though sodium nitroprusside is traditionally used to decrease 
SVR, low doses of dopamine or epinephrine are viable alternatives to patients with 
contraindications to nitroprusside infusions or who will require prolonged infusions 
to avoid toxicity. The multiple comparisons procedure-modeling approach is an excel-
lent methodology for dose-finding exercises and has enabled identification of equiva-
lent pharmacodynamic responses for epinephrine, dopamine, and sodium nitroprus-
side through mathematic simulations.
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i n t r o d u c t i o n
Sodium nitroprusside (SNP) is a nitric oxide (NO) releas-
ing drug used in medicine to therapeutically decrease blood 
pressure in cases of malignant hypertension.1,2 Exogenous 
administration of nitric oxide elicits effects such as dilation 
of both arterial and venous vessels and adverse effects such 
as inhibition of platelet aggregation potentially leading to 
prolonged bleeding in patients; however, despite these effects, 
SNP maintains high efficacy in the clinical setting.3,4 From 
a signaling perspective, NO released from an SNP infusion 
interacts predominately with iron and heme leading to the 
activation of soluble guanylyl cyclase (GC) forming protein 
kinase G.5 Following a series of reactions, the eventual 
outcome is a decrease in calcium within the cytosol causing 
reduced smooth muscle contractions within the vasculature. 
As an endogenous substance, nitric oxide provides the body 
with antithrombotic, antiatherogenic, and vasodilating effects 
rendering tremendous latitude for the demands of daily life.3–5
The two other vasodilators, at low doses, presented in this 
paper, are the catecholamines dopamine and epinephrine. 
At low doses, epinephrine acts via the G-protein coupled 
β2-adrenergic (ADRB2) receptors causing vasodilation 
through mediation by class CL-type calcium channels.6 There 
is much evidence describing polymorphisms associated with 
the ADRB2 gene potentially leading to varied clinical out-
comes ranging from asthma, chronic obstructive pulmonary 
syndrome, labor pain and progress, to patient survival in 
patients receiving beta-blocker therapy after acute coronary 
syndrome.7–9 Despite these findings, low dose epinephrine 
stimulates the ADRB2 resulting in vasodilation, providing 
strong inotropic support post cardiac surgery while maintain-
ing cerebral perfusion pressure, amongst other indications.
Dopamine, a precursor to both norepinephrine and epi-
nephrine, stimulates the DA1 and DA2 receptors resulting in 
vasodilation at low doses.10 Just as with epinephrine, at higher 
doses, the alpha-adrenergic receptor mediated vasoconstric-
tion predominates eliminating the vasodilating actions of the 
lower doses of both catecholamines. In the catecholamine 
synthesis pathway, phenylalanine is converted to tyrosine and 
subsequently dihydroxyphenylalanine, commonly referred to 
as dopa, an agent able to cross the blood brain barrier.11,12 
Further, in the conversion from dopa to dopamine, vitamin 
B6 is the necessary cofactor.13 Similarly, for the conversion 
of dopamine to norepinephrine, vitamin C is the required 
cofactor. As with all reactions, deficiencies of these cofactors 
result in build-up of the precursor and decrease in the down-
stream product. The last conversion from norepinephrine 
to epinephrine requires S-adenosyl methionine (SAM) as a 
cofactor where the formation of methionine is dependent on 
vitamin B12, a cofactor, from the conversion from homocyst-
eine to methionine.12,13 Thus, the common theme indicates that 
nutrition has an obvious importance along the catecholamine 
synthesis pathway and vitamin deficiencies along the conver-
sion steps may lead to a build-up or depressed levels of dopa, 
dopamine, norepinephrine, or epinephrine. Moreover, a recent 
review article summarizes ascorbate’s role as a cofactor for 
enzymes in the catecholamine synthesis pathway and recom-
mends ascorbate-dependent vasopressor support in patients 
with severe sepsis and septic shock.14
Dopamine DA1 and DA2 receptors are found in the brain, 
while higher receptor densities are located in the renal vascula-
ture smooth muscle allowing for increased blood flow with low 
infusion doses of dopamine.15,16 Therefore, the drug effects of 
nitroprusside, epinephrine, and dopamine have varied mecha-
nisms all allowing for dilation in the human vasculature. What 
are the equivalent doses allowing for decreasing vascular tone? 
The aim of this paper is to use mathematical modeling of 
established dose-response parameter values to then conduct 
simulations to identify the equivalent doses of dopamine, epi-
nephrine, and sodium nitroprusside to decrease the systemic 
vascular resistance (SVR) by 20% and by 40%. The hypothesis 
was that all three drugs would be capable of achieving a 20% 
and a 40% decrease in the change from SVR from resting 
values.
M e t h o d s
l i t e r A t u r e - b A s e d  d A t A  s o u r c e
Dose-response data were derived from three publications 
evaluating the effects of epinephrine, dopamine, and sodium 
nitroprusside on systemic vascular resistance as well as other 
hemodynamic variables.17–19 Results were originally reported 
in dynes*sec/cm5 and were scaled from the resting/baseline 
SVR to each respective dose response. Drug doses were all 
normalized to microgram per kilogram per minute (mcg/kg/
min) infusion doses. As a result of similar dose ranges, nitro-
prusside and dopamine results are illustrated on the same 
dose-response curves; however, epinephrine was reported on 
a single dose-response curve. Lastly, box and whisker plots 
depicting the equivalent doses resulting in an approximate 20% 
decrease in SVR, for all three drugs, and an approximate 40% 
decrease in SVR for epinephrine and sodium nitroprusside.
P h A r M A c o k i n e t i c / P h A r M A c o d y n A M i c 
M o d e l i n g  A n d  d o s e - r e s P o n s e 
s i M u l A t i o n s
Pharmacokinetic/pharmacodynamic (PK/PD) modeling 
and simulations were conducted in the R programming lan-
guage (version 3.2.2, The R Foundation for Statistical Com-
puting, Vienna, Austria).20,21 Specifically, the dose-response 
simulations were conducted using the Multiple Comparisons 
Procedure-Modeling package in R.22 This modeling package 
has been validated by the European Medicines Agency (EMA) 
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Committee for Medicinal Products for Human Use and is 
used during clinical trials.23 Based on the EMA qualification 
report, the committee determined the R package an efficient 
statistical tool for Phase II dose finding studies. The Multiple 
Comparisons Procedure allows for population dose-response 
testing and estimation of model uncertainties by enabling re-
searchers to design candidate models in clinical trial design.22,24 
Lastly, for all dose-response simulations, a sample size of 100 
virtual patients (n=100) was created at each infusion dose.
equation 1: Pharmacodynamic modeling equation describ-
ing the percent decrease in the systemic vascular resistance 
(SVR) based on infusion doses of epinephrine, dopamine, or 
sodium nitroprusside. 
r e s u l t s
The dose-response simulations resulted in 1100 samples for 
dopamine, 1000 samples for epinephrine, and 1300 samples for 
nitroprusside. The infusion doses normalized to mcg/kg/min 
with the corresponding SVR percent change from baseline are 
reported in Table 1. The original Epinephrine dose-response 
values were obtained from the Stratton et al18 1985 study that 
was conducted in 10 healthy participants. This study evalu-
ated the hemodynamic outcomes following infusion of three 
different epinephrine doses (25, 50, and 100 ng/kg/min).For 
the original Sodium Nitroprusside data, the values are refer-
enced from the Gerson et al 1982 study in 20 adult patients 
undergoing elective open heart surgery.17 The original study 
methods indicate that none of the patients received any drug 
for at least 11 hours prior to the study  period. Therefore, the 
dose-response simulations are based on a patient population, 
rather than in healthy participants. 
As with the nitroprusside clinical population, the original 
dose-response values referenced for the  Dopamine data were 
obtained from the Elkayam et al 2008 study in 13 patients with 
a history of congestive heart failure (CHF).19 In these patients, 
CHF was due to left ventricular systolic dysfunction with 
moderate to severe symptoms (New York Heart Association 
functional class III or IV) with left ventricular ejection fraction 
ranging from 14% to 32%.19 Moreover, the underlying cause 
of CHF was coronary artery disease (n=5) and non-ischemic 
dilated cardiomyopathy (n=8).19 For the original dopamine 
study, all 13 patients were treated with diuretics, 10 were on 
ACE inhibitors (n=10), nine were medicated with digoxin 
(n=9), seven were on beta-blockers (n=7), and lastly, seven 
were treated with organic nitrates (n=7).19 Therefore, to 
summarize, healthy participants were evaluated in the epi-
nephrine study, while both the dopamine and nitroprusside 
dose-response data were collected in patients with cardiovas-
cular conditions.17–19
The R programming language scripts were written creat-
ing the resulting model parameters and model diagnostics 
Akaike Information Criteria (AIC) and fitted Log-likelihood. 
The results are provided in Table 2. Overall, the Emax model 
equation adequately described the dose-response data from 
the overall published studies. The best Log-likelihood fit in 
decreasing order is as follows: epinephrine, dopamine, and 
nitroprusside, respectively. The maximum decrease in the 
percent SVR model parameter (SVRmax) resulted in a very 
wide standard error for nitroprusside; this finding clinically 
makes sense due to the powerful vasodilating effects of the 
drug. At doses less than 2 mcg/kg/min, dopamine and nitro-
prusside exhibited a near parallel linear curve, however, at 
around 2 mcg/kg/min, the population dose-response simula-
tions diverged resulting in dopamine’s vasodilation effects 
ending near 10 mcg/kg/min.
Figure 1 provides the dose response simulation results 
for both dopamine and sodium nitroprusside infusions to 
systemic vascular resistance. There is a clear dose dependent 
decrease in SVR as epinephrine is infused at doses lower than 
tAble 1. Normalized Published Dose-Response Data Sources Used for Modeling and Simulations. Systemic Vascular 
Resistance (SVR) Responses Represent % Vasodilation
dopamine  epinephrine  sodium nitroprusside
elkayam et al (2008)19 stratton et al (1985)18 gerson et al (1982)17
dose 
(mcg/kg/min)
response 
(% sVr)
dose
(mcg/kg/min)
response
(% sVr)
dose
(mcg/kg/min)
response
(% sVr)
0 100 0 100 0 100
1 83 0.025 69 1 94
2 82 0.050 58 1.5 87
3 81 0.100 52 2 82
10 77 -- -- -- --
4HOSPITAL CHRONICLES 11(1), 2016
0.010 mcg/kg/min. It is important to note that the epinephrine 
dose-response model parameters are valid for doses at or below 
0.010 mcg/kg/min. Higher simulation doses were attempted 
and, as expected, an increase in the %SVR was seen with 
wider shaded confidence interval bands. Therefore, due to 
the predominant alpha-adrenergic receptor effects at higher 
epinephrine infusion doses, the mathematical model becomes 
unstable and is therefore recommended for infusion doses 
of less than 0.10 mcg/kg/min. However, despite the higher 
dose simulation findings, the mathematical model allowed 
for appropriate hypothesis testing and addressing the aim 
of identifying doses resulting in a 20% and 40% decrease in 
systemic vascular resistance.
Based on the mathematical simulations, the doses result-
ing in an equivalent infusion response leading to decreased 
systemic vascular resistance by 20-25%, are 5 mcg/kg/min 
for dopamine, 0.015 mcg/kg/min for epinephrine, and lastly 
2.5 mcg/kg/min for sodium nitroprusside. These results are 
based on the median simulated population response rate 
and variations with infusion outcomes would potentially be 
tAble 2: Calculated Dose-Response Modeling Parameters and Diagnostics
dopamine epinephrine sodium nitroprusside
SVRmax (%) (S.E.) -22.894 (2.037) -59.0303 (2.75) -52.2 (120.54)
SVR0 (%) (S.E.) 99.954 (1.384) 100.0420 (1.14) 101.3 (3.89)
ED50 (mcg/kg/min) (S.E.) 0.432 (0.177) 0.0218 (0.0034) 4.0 (13.39)
Akaike Information Criterion 20.8632 24.6809 14.8374
Fitted Log-likelihood -6.4316 -3.4187 -8.3405
ED50 = 50% effective dose; SE = standard error; SVR = systemic vascular resistance; SVR0 = effect at baseline dose; SVRmax = dose resulting 
in maximum effect
Figure 1. Dose-response simulation results comparing the effect of Dopamine and Sodium Nitroprusside on the percent change, 
from baseline, of systemic vascular resistance. The solid line describes the population mean while the shaded error bands represent 
the 95% confidence intervals.
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Figure 2. Dose-response simulation results comparing the effect of Epinephrine on the percent change, from baseline, of systemic 
vascular resistance. The solid line describes the population mean while the shaded error bands represent the 95% confidence intervals.
Figure 3. Approximate equivalent doses resulting in a 20-25% decrease in systemic vascular resistance for Dopamine (5 mcg/kg/
min), Epinephrine (0.015 mcg/kg/min), and Sodium Nitroprusside (2.5 mcg/kg/min). The box plots represent 25%, 50% (median), and 
75th percentile values, while the whisker lines represent the 10th and 90th percentile results. The dots represent the population outliers.
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erties of epinephrine, dopamine, and sodium nitroprusside 
based on dose-response simulations. These three drugs, all al-
lowing for the same outcome variable of a decrease in systemic 
vascular resistance (SVR), all work with various mechanisms 
allowing for the same response. These principles highlight the 
role that endogenous nitric oxide, epinephrine, and dopamine 
play in maintaining vascular tone and further suggest the pos-
sibility to investigate a multi-mechanism approach for drug 
development to combat treatment resistant hypertension.
Understanding the mechanisms underlying essential hy-
pertension has been investigated and treatments have been 
proposed for several decades using various medical and surgi-
cal approaches. The first measurement of blood pressure was 
accomplished in 1733 by Stephen Hales, an English clergyman27 
and has remained key pillar of human health since that time. In 
the 1930s, nearly 200 years later from the first blood pressure 
measurement, a common approach to management of hyper-
tension was renal sympathectomy,28 the approach of surgically 
denervating the kidney. Other approaches at the time were 
inducing high fevers in patients by using the typhoid bacilli or 
malaria related substances.29,30 Since then, pharmacological 
approaches have been quite successful; however, in select 
patients even individual combination of anti-hypertensive 
medications are of no help. These patients are classified as 
having resistant essential hypertension and often suffer from 
associated with gender and/or genotype status of the Catechol-
O-methyltransferase (COMT) and/or Monoamine oxidase 
(MAO) enzymes when using dopamine or epinephrine.25 Due 
to the effect on cardiac output by epinephrine and dopamine, 
cases necessitating maintenance of cerebral perfusion pressure, 
these two catecholamines are therapeutic alternative vasodila-
tors to sodium nitroprusside.
After analyzing the response rates of the dopamine infu-
sion simulations, the results suggest that the alpha-1 receptor 
vasoconstriction effects at around 10 mcg/kg/min. Therefore, 
in addressing the second aim, the equivalent dose resulting in 
a 40% decrease in SVR from baseline is 0.040 mcg/kg/min of 
epinephrine and a maximum infusion dose of 10 mcg/kg/min 
for sodium nitroprusside. As with any drug, population outliers 
are evident, and therefore, careful titration of these aforemen-
tioned infusion doses will be critical due to the extreme and 
rare instances when a 40% drop of SVR from baseline may 
be desired by the clinical staff. The dopamine simulation dose 
findings are consistent with the package insert for nitroprus-
side indicating a maximum infusion dose at 10 mcg/kg/min.26
d i s c u s s i o n
This paper described the dose-matched vasodilating prop-
Figure 4. Approximate equivalent doses resulting in nearly a 40% decrease in systemic vascular resistance for Epinephrine (0.040 
mcg/kg/min) and for infusions of Sodium Nitroprusside (10 mcg/kg/min). The box plots represent 25%, 50% (median), and 75th 
percentile values, while the whisker lines represent the 10th and 90th percentile results. The dots represent the population outliers.
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the deleterious effects on various organs of the body due to 
chronically high blood pressures. 
Mathematically, the change in pressure equals the blood 
flow multiplied by the vascular resistance, parameters that 
are all dependent on the vasodilatory capacity of the vessel 
and also organ-dependent. The brain and kidney have a low 
vasodilatory capacity and therefore have low vascular tone. 
In contrast, the heart and skeletal muscle are capable of high 
vasodilatory capacity resulting in high vascular tone. Thus, 
the modulation of resting vascular tone varies depending on 
the organ of interest, which in turn, is influenced by both en-
dogenous substances (i.e. nitric oxide, epinephrine, etc.) and 
is regulated by sympathetic neurons located in the medulla 
regulating changes in vascular diameter.
Endogenous and exogenous substances, emotional well-
being, environmental influences, and lifestyle factors all result 
in competing mechanisms resulting in essential hypertension. 
In this paper, the primary summarized dependent variable was 
systemic vascular resistance relative to the drug dosing (inde-
pendent variable). As stated by the EMA report, there is a clear 
role for the mathematical simulations throughout the drug 
development and dose-finding process. This exercise clearly 
exhibited the cost-savings involved using interdisciplinary 
skills in computer programming, mathematics, and medicine 
to make recommendations for drug doses. The results are 
not supporting any of the three vasodilators over the other; 
however, there are clear physiologic benefits to choosing any 
of the three vasodilators in the appropriate clinical indication.
Based on the results, the hypothesis-testing results indicate 
that clearly epinephrine, dopamine, and sodium nitroprus-
side are able to decrease SVR by 20%. However, due to the 
increased alpha-1 vasoconstriction effects of dopamine near 
10 mcg/kg/min, a 40% decrease in SVR was not evident based 
on the dose-response simulations. Rather, a 0.040 mcg/kg/min 
infusion of epinephrine provided the dose-response equiva-
lence results to a 10 mcg/kg/min of nitroprusside.
c o n c l u s i o n
Equivalent pharmacodynamic SVR responses have been 
identified for epinephrine, dopamine, and sodium nitroprus-
side using the multiple comparisons procedure-modeling 
approach. Based on the simulations, low-dose epinephrine 
or low-dose dopamine may provide clinicians without access 
to nitroprusside with more options to decrease patients’ SVR 
and maintain adequate cerebral perfusion pressure, for the 
appropriate clinical indications.
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